Bristol-Myers Squibb ranks first on 2014 Best Corporate Citizens List

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders. Bristol-Myers Squibb is the only company to achieve the No. 1 ranking three times, including 2009 and 2012, and has ranked among the top 10 each of the last six years.

The 100 Best Corporate Citizens list ranks companies in the Russell 1000 using nearly 300 data points in seven categories: environment, climate change, employee relations, human rights, governance, finance, and philanthropy.

"We are proud to again be recognized for our commitment to social responsibility and corporate citizenship," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "Our efforts to promote economic, social and environmental sustainability are core to our company's mission and reflect our ongoing commitment to patients, our employees and partners, the environment, and communities around the world."

Investors, customers, suppliers, regulators, employees and other stakeholders use the list to assess how well publicly traded companies hold themselves accountable in these seven important categories while also enabling shareholders and other stakeholders to make more informed decisions.

"At Bristol-Myers Squibb, the principles that make us a top corporate citizen are well established in the company's culture and values," said Susan Voigt, vice president, Environment, Health, Safety and Sustainability. "Our employees are deeply involved in many social responsibility initiatives and committed to conducting our business in an ethical and sustainable manner."

Bristol-Myers Squibb's commitment to sustainable, ethical and compliant global business practices serves as the foundation of the company's Sustainability 2015 goals, which continue to build upon the accomplishments of previous Sustainability goals.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global specialty care biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...